About Topas Therapeutics
Topas Therapeutics is a Technology company based in Hamburg (Germany) founded in 2016. Nanoparticle-based therapeutics for immunology disorders are developed. It operates in the Technology and Healthcare sectors. Topas Therapeutics has raised $67.46 million across 6 funding rounds from investors including Evotec, Gimv and European Union. The company has 14 employees. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science.
Company details
Founded in 2016 and based in Hamburg, Germany, nanoparticle-based therapeutics targeting immunology disorders are developed. Operations focus on the biotech sector, with a pipeline that includes TPM 203 for pemphigus vulgaris, TPM 501502 for celiac disease, and interventions for anti-drug immune responses. Research and development activities are centered on advancing these candidates toward clinical applications in immune-related conditions.
- Headquarters Hamburg, Germany
- Employees 14
- SectorsTechnologyHealthcare
- Email••••••••
- Website topas-therapeutics.com
- Social LinkedIn
- Total Equity Funding$67.46M (USD)
in 6 rounds
- Latest Funding Round$21.27M (USD), Series B
Jul 2021
- InvestorsEvotec
& 7 more
- Employee Count14
Funding Insights of Topas Therapeutics
Topas Therapeutics has successfully raised a total of $67.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $21.27 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.46M
- Total Rounds 6
- Last Round Series B — $21.27M
- First Round $15.77M
(Mar 2016)
- Investors Count 8
All 6 funding rounds of Topas Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $21.27M | Series B | – | – | – |
| Mar 2021 | $492,082 | Grant | – | – | |
| Oct 2020 | $25.77M | Series B | – | Vesalius Biocapital III, BioMedPartners | – |
| Apr 2020 | $290,798 | Grant | – | – | |
| Nov 2017 | $4.65M | Series A | – | Boehringer Ingelheim Venture Fund | – |
| Mar 2016 | $15.77M | Series A | – | Epidarex Capital |
8 investors in total: 8 institutional.
Investors in Topas Therapeutics
Topas Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, Gimv and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A European life sciences venture capital investor is operated. | 2017 | vesaliusbiocapital-3.com | Strassen, Luxembourg | |
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
| epidarex.com | ||||
Life science companies are supported through strategic investments. | embl-ventures.com | Heidelberg, Germany | ||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Drug discovery and development services are provided to biopharma sector. | 1993 | evotec.com | Hamburg, Germany |
Investor details for Topas Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Topas Therapeutics
12 people are tracked at Topas Therapeutics (6 in leadership, 6 in team); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Christian Schroeter | Chief Operating Officer & Managing Director | Leadership |
Gerhard Wallner | Head of Manufacturing | Leadership |
Debora Lage | Executive Assistant To Chief Executive Officer | Leadership |
Dikran Sarko | Head of Nanotechnology | Leadership |
Veronica Asnaghi | Head of Clinical Science | Leadership |
Siegfried Roesch | Head Of Clinical Operations | Leadership |
Dr. rer. nat. Artem Shaposhnykov | Research Scientist | Team |
Maria Theresa Sarmento Toledo | Administration and Finance Manager | Team |
Dr. Muhammad Alsamman | Business Operations Manager | Team |
Shu-Hung Wang | Research Scientist, translational medicine | Team |
Marco Fanzutti | Project Manager | Team |
Daria Krzikalla | Senior Project Manager | Team |
Complete people profiles for Topas Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Topas Therapeutics
3 dated milestones of Topas Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Topas Therapeutics is founded.
- Funding First funding round of $15.8M.
- Funding Latest funding round, Series B, of $21.3M.
Web traffic of Topas Therapeutics
The website of Topas Therapeutics (topas-therapeutics.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 41% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Topas Therapeutics
Complete news archive for Topas Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Topas Therapeutics
Topas Therapeutics was founded in 2016.
Topas Therapeutics is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Topas Therapeutics is a funded company, having raised a total of $67.46M across 6 funding rounds to date. The company's 1st funding round was a Series A of $15.77M, raised on Mar 2016.
Topas Therapeutics has 14 employees.
Founded in 2016 and based in Hamburg, Germany, nanoparticle-based therapeutics targeting immunology disorders are developed. Operations focus on the biotech sector, with a pipeline that includes TPM 203 for pemphigus vulgaris, TPM 501502 for celiac disease, and interventions for anti-drug immune responses. Research and development activities are centered on advancing these candidates toward clinical applications in immune-related conditions.
Topas Therapeutics has 8 investors. Key investors include Evotec, Gimv, European Union, Vesalius Biocapital, and BioMedPartners.